A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
At a glance
- Drugs TAK 041 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 10 May 2018 Planned End Date changed from 3 Jun 2019 to 31 Oct 2019.
- 19 Jan 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 New trial record